Ligand to Present at Upcoming Investor Conferences
Needham Healthcare Conference 2013
SAN DIEGO -- April 23, 2013
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that John
Higgins, President and Chief Executive Officer of Ligand, is scheduled to
present at the following upcoming investor conferences:
*12^th Annual Needham Healthcare Conference in New York, NY. Presentation:
Tuesday, April 30, 2013 at 8:00 a.m. Eastern (5:00 a.m. Pacific).
*Bank of America Merrill Lynch 2013 Healthcare Conference in Las Vegas, NV.
Presentation: Wednesday, May 15, 2013 at 2:20 p.m. Eastern (11:20 a.m.
A live webcast of these presentations will be available on Ligand’s website at
www.ligand.com. A replay of the presentations will be archived there for 30
About Ligand Pharmaceuticals
Ligand is a biopharmaceutical company that develops and acquires assets it
believes will generate royalty revenues and, under its lean corporate cost
structure, produce sustainable profitability. Ligand has a diverse asset
portfolio addressing the unmet medical needs of patients for a broad spectrum
of diseases including thrombocytopenia, multiple myeloma, diabetes, hepatitis,
muscle wasting, dyslipidemia, anemia and osteoporosis. Ligand’s Captisol
platform technology is a patent-protected, chemically modified cyclodextrin
with a structure designed to optimize the solubility and stability of drugs.
Ligand has established multiple alliances with the world's leading
pharmaceutical companies including GlaxoSmithKline, Onyx Pharmaceuticals,
Merck, Pfizer, Baxter International, Bristol-Myers Squibb, Celgene, Lundbeck
Inc., Eli Lilly & Co., Spectrum Pharmaceuticals and The Medicines Company.
Please visit www.captisol.com for more information on Captisol or
www.ligand.com for more information on Ligand.
Follow Ligand on Twitter @Ligand_LGND.
Ligand Pharmaceuticals Incorporated
John Higgins, President and CEO
Jennifer Capuzelo, Investor Relations
Press spacebar to pause and continue. Press esc to stop.